Larimar Therapeutics Unveils Long‑Term Nomlabofusp Data for Friedreich’s Ataxia at ICAR 2026
Discover Larimar Therapeutics’ interim nomlabofusp data for Friedreich’s ataxia, including efficacy, safety, lipid biomarkers, and gene‑expression insights, presented at ICAR 2026.
2 minutes to read
